All in all, our study verified the significant carcinogenic role of TP73-AS1 in the progression of LAD depending on PI3K/AKT signaling pathway, indicating TP73-AS1 as a novel prognostic biomarker and therapeutic target for LAD patients. Here, TP73 is linked to leukocyte adhesion deficiency.